
VRTX — Vertex Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$543.50
+$1.81 (+0.33%)
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on NASDAQ. It is led by Reshma Kewalramani FASN, M.D., based in 50 Northern Avenue, Boston, MA, United States, 02210, with about 6,100 employees. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Latest reported VRTX revenue for 2026-03-31 was $2.99B. Net income was $1.03B. Revenue was down 75.1% from 2025-12-31 to 2026-03-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Use this VRTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VRTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VRTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Vertex Pharmaceuticals Inc even when a live quote feed is slow.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
VRTX Key Statistics
Market Cap
$106.87B
P/E Ratio
29.67
Employees
6,100
Vertex Pharmaceuticals Inc Company Information
- CEO, President & Director
- Reshma Kewalramani FASN, M.D.
- Headquarters
- 50 Northern Avenue, Boston, MA, United States, 02210
- Website
- www.vrtx.com
- Phone
- 617 341 6100
- IPO / Founded
- 1991-07-24
- Sector
- Healthcare
- Industry
- Biotechnology